IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease and other ischaemic conditions, has appointed Dr. Gary Burgess as Chief Medical Officer (CMO). Burgess has over two decades of experience spanning all phases of drug development, from Phase 1 to Phase 4, in a diverse range of diseases and therapeutic areas. Throughout this journey, he has maintained close collaboration with regulatory agencies, ...